Amylyx Pharmaceuticals vs Rhythm Pharmaceuticals
AMLX and RYTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMLX and RYTM compare
Rhythm Pharmaceuticals is the larger company, worth 2.3 times as much as Amylyx Pharmaceuticals ($7.6B against $3.3B).
Amylyx Pharmaceuticals scores higher on the StockData Score (7 against 5 for Rhythm Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMLX | RYTM |
|---|---|---|
| Size and price | ||
| Market cap | $3.3B | $7.6B |
| Share price | $29.86 | $109.86 |
| Change, 1 year | 135% | 10.0% |
| Change, 5 years | 178% | 967% |
| Beta (5Y) | 1.15 | 1.40 |
| Employees | 136 | 414 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 31.5× |
| P/B | 4.4× (better) | 73.4× |
| Fair value | – | $31.52 |
| Margin of safety | – | −249% |
| Growth | ||
| Revenue growth (TTM) | – | 53.5% |
| Profitability | ||
| Gross margin | – | 89.0% |
| Operating margin | – | −83.6% |
| Net margin | – | −85.6% |
| Return on equity | −30.1% (better) | −451% |
| Financial health | ||
| Debt / equity | 0.00 | 1.03 (better) |
| Interest coverage | – | −10.9× |
| Current ratio | 26.81 (better) | 3.45 |
| Altman Z-score | 59.22 (better) | 15.83 |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 112% |
| Held by insiders | 8.0% | 1.1% |
| Insider net buying, 12 months | −$10.0M (better) | −$36.0M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 12.5% | 17.1% |
Go deeper
- AMLX stock overview
- AMLX income statement
- AMLX valuation and score
- RYTM stock overview
- RYTM income statement
- RYTM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.